Antitumor Activity of Tasurgratinib as an Orally Available FGFR1-3 Inhibitor in Cholangiocarcinoma Models With FGFR2-fusion
Article in Anticancer Research (May 2024)
The most recent citing publications are shown below. View all 6 publications that cite this research output on Dimensions.
Research progress on the animal model and organoid of intrahepatic cholangiocarcinoma
Article in Chinese Journal of Experimental Surgery (October 2023)
Cancer “Avatars”: Patient-Derived Xenograft Growth Correlation with Postoperative Recurrence and Survival in Pancreaticobiliary Cancer
Article in Journal of the American College of Surgeons (June 2023)